AGIOS PHARMACEUTICALS, INC. ($AGIO)
Filing Information
| Accession Number | 0001439222-26-000036 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 3, 2026 |
| Document | View SEC Filing |
Transactions
8
Total Shares
88,200
Total Value
$83,057.28
P&L
+inf% (+$1,838,760.00)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer | Common stock | โ | Mar 2, 2026 | Exercise/Conversion | 5,666 | $0.00 | $0.00 | 40,459 | Direct | โ | View Details | |
Chief Commercial Officer | Common stock | โ | Mar 2, 2026 | Sale | 1,681 | $28.96 | $48,681.76 | 38,778 | Direct | โ | View Details | |
Chief Commercial Officer | Common stock | โ | Mar 2, 2026 | Exercise/Conversion | 4,000 | $0.00 | $0.00 | 42,778 | Direct | โ | View Details | |
Chief Commercial Officer | Common stock | โ | Mar 2, 2026 | Sale | 1,187 | $28.96 | $34,375.52 | 41,591 | Direct | โ | View Details | |
Chief Commercial Officer | Restricted stock units | Derivative | Mar 1, 2026 | Grant/Award | 14,000 | $0.00 | $0.00 | 14,000 | Direct | โ | View Details | |
Chief Commercial Officer | Stock options (right to buy) | Derivative | Mar 1, 2026 | Grant/Award | 52,000 | $0.00 | $0.00 | 52,000 | Direct | โ | View Details | |
Chief Commercial Officer | Restricted stock units | Derivative | Mar 2, 2026 | Exercise/Conversion | 5,666 | $0.00 | $0.00 | 5,667 | Direct | โ | View Details | |
Chief Commercial Officer | Restricted stock units | Derivative | Mar 2, 2026 | Exercise/Conversion | 4,000 | $0.00 | $0.00 | 8,000 | Direct | โ | View Details |